Top of this page
Skip navigation, go straight to the content
Categories
-
2012 gets off on the right foot
Posted by Antje Witte, Investor Relations 26-Apr-2012
Net sales of UCB’s three core medicines were up 50% in the first three months of 2012 compared with the same period last year. That’s one of take-home messages for the year so far. The other one is a significant pipeline performance.
-
Introducing the UCB Annual Report 2.0
Posted by Isabelle Ghellynck, Investor Relations 08-Mar-2012
For the first time, the UCB Annual Report is an "online" publication. More visual and more concise, we’ve made it easier to use and saved some trees in the process.
-
2011 was a good year for UCB
Posted by Antje Witte, Investor Relations 02-Mar-2012
Last year was another good one - paving the way for sustainable company growth -
Sharing the good news…
Posted by Antje Witte, Investor Relations 23-Jan-2012
Where did the Christmas holidays go? Somehow it’s almost February already but at least January brought a major piece of good news: we won an award!
-
Q3 financial results show UCB is on track
Posted by Antje Witte, Investor Relations 27-Oct-2011
-
UCB 'on the road again'
Posted by Antje Witte, Investor Relations 13-Sep-2011
-
UCB delivers strong results
Posted by Antje Witte, Investor Relations 29-Jul-2011
-
UCB off to good start in 2011
Posted by Antje Witte, Investor Relations 29-Apr-2011
Financial figures published on April, 28 reveal UCB got off to a strong start with total revenue increasing by 13% to €893 million in the first quarter of the year. -
2010 Annual Report
Posted by Antje Witte, Investor Relations 29-Apr-2011
Annual Report shows UCB’s biopharma aspirations on trackThe 2010 Annual Report is now available on the UCB website. Offering more than just financial results, this year’s report highlights and analyses UCB’s 2010 activities as it advanced its goals of becoming the patient-centric biopharmaceutical leader.
